{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:35:35Z","timestamp":1790796935940,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s10072-021-05105-5","type":"journal-article","created":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T21:22:37Z","timestamp":1612819357000},"page":"4193-4202","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study"],"prefix":"10.1007","volume":"42","author":[{"given":"Maria Michela","family":"Cainazzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8432-1888","authenticated-orcid":false,"given":"Carlo","family":"Baraldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Lo Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Pani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Guerzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,5]]},"reference":[{"key":"5105_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38:1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202","journal-title":"Cephalalgia"},{"key":"5105_CR2","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/nrneurol.2016.124","volume":"12","author":"HC Diener","year":"2016","unstructured":"Diener HC, Holle D, Solbach K, Gaul C (2016) Medication-overuse headache: risk factors, pathophysiology and management. Nat Rev Neurol 12:575\u2013583. https:\/\/doi.org\/10.1038\/nrneurol.2016.124","journal-title":"Nat Rev Neurol"},{"key":"5105_CR3","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1111\/j.1526-4610.2012.02223.x","volume":"52","author":"DC Buse","year":"2012","unstructured":"Buse DC, Manack AN, Fanning KM, Serrano D, Reed ML, Turkel CC, Lipton RB (2012) Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache 52:1456\u20131470. https:\/\/doi.org\/10.1111\/j.1526-4610.2012.02223.x","journal-title":"Headache"},{"key":"5105_CR4","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s11916-013-0385-0","volume":"18","author":"Lanteri-Minet","year":"2014","unstructured":"Lanteri-Minet (2014) Economic burden and costs of chronic migraine. Curr Pain Headache Rep 18:358. https:\/\/doi.org\/10.1007\/s11916-013-0385-0","journal-title":"Curr Pain Headache Rep"},{"key":"5105_CR5","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1177\/0333102417737779","volume":"38","author":"LN Carlsen","year":"2018","unstructured":"Carlsen LN, Munksgaard SB, Jensen RH, Bendtsen L (2018) Complete detoxification is the most effective treatment of medication- overuse headache: a randomized controlled open-label trial. Cephalalgia 38:225\u2013236. https:\/\/doi.org\/10.1177\/0333102417737779","journal-title":"Cephalalgia"},{"key":"5105_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s10194-018-0899-2","volume":"20","author":"TJ Steiner","year":"2019","unstructured":"Steiner TJ, Jensen R, Katsarava Z, Linde M, MacGregor EA, Osipova V, Paemeleire K, Olesen J, Peters M, Martelletti P (2019) Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting The Burden: The Global Campaign Against Headache. J Headache Pain 20:57. https:\/\/doi.org\/10.1186\/s10194-018-0899-2","journal-title":"J Headache Pain"},{"key":"5105_CR7","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s40265-018-0944-0","volume":"78","author":"A Markham","year":"2018","unstructured":"Markham A (2018) Erenumab: first global approval. Drugs 78:1157\u20131161. https:\/\/doi.org\/10.1007\/s40265-018-0944-0","journal-title":"Drugs"},{"key":"5105_CR8","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","volume":"16","author":"S Tepper","year":"2017","unstructured":"Tepper S, Ashina M, Reuter U, Brandes JL, Dole\u017eil D, Silberstein SD, Winner P, Leonardi D, Mikol D, Lenz R (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16:425\u2013434. https:\/\/doi.org\/10.1016\/S1474-4422(17)30083-2","journal-title":"Lancet Neurol"},{"key":"5105_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1212\/WNL.0000000000007497","volume":"92","author":"SJ Tepper","year":"2019","unstructured":"Tepper SJ, Diener HC, Ashina M, Brandes JL, Friedman DI, Reuter U, Cheng S, Nilsen J, Leonardi DK, Lenz RA, Mikol DD (2019) Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial. Neurology 92:20\u2013e2320. https:\/\/doi.org\/10.1212\/WNL.0000000000007497","journal-title":"Neurology"},{"key":"5105_CR10","doi-asserted-by":"crossref","unstructured":"Schiano Di Cola F, Rao R, Caratozzolo S, Di Cesare M, Venturelli E, Balducci U, Sidoti V, Pari E, Costanzi C, Di Summa A, Sixt GJ, D\u2019Adda E, Liberini P, Padovani A Erenumab efficacy in chronic migraine and medication overuse: a real-life multicentric Italian observational study. Neurol Sci 41:489\u2013490","DOI":"10.1007\/s10072-020-04670-5"},{"key":"5105_CR11","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s10072-020-04690-1","volume":"41","author":"M Curone","year":"2020","unstructured":"Curone M, Tullo V, Bussone G (2020) Effectiveness of erenumab in chronic migraine patients with associated medication overuse headache: a prospective observational study. Neurol Sci 41:509\u2013510. https:\/\/doi.org\/10.1007\/s10072-020-04690-1","journal-title":"Neurol Sci"},{"key":"5105_CR12","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1177\/0333102418788347","volume":"38","author":"M Ashina","year":"2018","unstructured":"Ashina M, Tepper S, Brandes JL, Reuter U, Boudreau G, Dolezil D, Cheng S, Zhang F, Lenz R, Klatt J, Mikol DD (2018) Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia 38:1611\u20131621. https:\/\/doi.org\/10.1177\/0333102418788347","journal-title":"Cephalalgia"},{"key":"5105_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1212\/WNL.0000000000007452","volume":"92","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Tepper SJ, Reuter U, Silberstein S, Stewart WF, Nilsen J, Leonardi DK, Desai P, Cheng S, Mikol DD, Lenz R (2019) Erenumab in chronic migraine: patient-reported outcomes in a randomized double-blind study. Neurology 92:19\u2013e2260. https:\/\/doi.org\/10.1212\/WNL.0000000000007452","journal-title":"Neurology"},{"key":"5105_CR14","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1177\/0333102418796842","volume":"38","author":"M Sussman","year":"2018","unstructured":"Sussman M, Benner J, Neumann P, Menzin J (2018) Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: results from the US societal and payer perspectives. Cephalalgia 38:1644\u20131657. https:\/\/doi.org\/10.1177\/0333102418796842","journal-title":"Cephalalgia"},{"key":"5105_CR15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s10194-018-0955-y","volume":"20","author":"S Sacco","year":"2019","unstructured":"Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD, Martelletti P (2019) European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain 20:6. https:\/\/doi.org\/10.1186\/s10194-018-0955-y","journal-title":"J Headache Pain"},{"key":"5105_CR16","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1177\/0333102410379890","volume":"31","author":"M Yang","year":"2011","unstructured":"Yang M, Rendas-Baum R, Varon SF, Kosinski M (2011) Validation of the Headache Impact Test (HIT-6) across episodic and chronic migraine. Cephalalgia 31:357\u2013367. https:\/\/doi.org\/10.1177\/0333102410379890","journal-title":"Cephalalgia"},{"key":"5105_CR17","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s10194-018-0914-7","volume":"19","author":"A Raggi","year":"2018","unstructured":"Raggi A, Covelli V, Guastafierro E, Leonardi M, Scaratti C, Grazzi L, Bartolini M, Viticchi G, Cevoli S, Pierangeli G, Tedeschi G, Russo A, Barbanti P, Aurilia C, Lovati C, Giani L, Frediani F, Di Fiore P, Bono F, Rapisarda L, D\u2019Amico D (2018) Validation of a self-reported instrument to assess work-related difficulties in patients with migraine: the HEADWORK questionnaire. J Headache Pain 19:85. https:\/\/doi.org\/10.1186\/s10194-018-0914-7","journal-title":"J Headache Pain"},{"key":"5105_CR18","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1177\/0333102420912726","volume":"40","author":"SJ Tepper","year":"2020","unstructured":"Tepper SJ, Ashina M, Reuter U, Brandes JL, Dolezil D, Silberstein SD, Winner P, Zhnag F, Cheng S, Mikol DD (2020) Long-term safety and efficacy of erenumab in patients with chronic migraine: results from a 52-week, open-label extension study. Cephalalgia 40:543\u2013453. https:\/\/doi.org\/10.1177\/0333102420912726","journal-title":"Cephalalgia"},{"key":"5105_CR19","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3389\/fneur.2020.00417","volume":"1","author":"B Raffaelli","year":"2020","unstructured":"Raffaelli B, Kalantzis R, Mecklenburg J, Hendrik Overeem L, Neeb L, Gendolla A, Reuter U (2020) Erenumab in chronic migraine patients who previously failed five first-line oral prophylactics and onabotulinumtoxinA: a dual-center retrospective observational study. Front Neurol 1:417. https:\/\/doi.org\/10.3389\/fneur.2020.00417","journal-title":"Front Neurol"},{"key":"5105_CR20","doi-asserted-by":"publisher","unstructured":"Garces F, Mohr C, Zhang L, Huang CS, Chen Q, King C, Xu C, Wang Z (2020) Molecular insight into recognition of the CGRPR complex by migraine prevention therapy Aimovig (erenumab). Cell Rep 30:1714\u20131723. https:\/\/doi.org\/10.1016\/jcelrep.2020.01.029","DOI":"10.1016\/jcelrep.2020.01.029"},{"key":"5105_CR21","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s10194-015-0576-7","volume":"16","author":"D Wan","year":"2015","unstructured":"Wan D, Hou L, Zhang X, Han X, Chen M, Tang W, Liu R, Dong Z, Yu S (2015) DNA methylation of RAMP1 gene in migraine: an exploratory analysis. J Headache Pain 16:90. https:\/\/doi.org\/10.1186\/s10194-015-0576-7","journal-title":"J Headache Pain"},{"key":"5105_CR22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s10194-020-01151-0","volume":"21","author":"A Scheffler","year":"2020","unstructured":"Scheffler A, Messel O, Wurthmann S, Nsaka M, Kleinschnitz C, Glas M, Naegel S, Holle D (2020) Erenumab in highly therapy-refractory migraine patients: first German real-world evidence. J Headache Pain 21:84. https:\/\/doi.org\/10.1186\/s10194-020-01151-0","journal-title":"J Headache Pain"},{"key":"5105_CR23","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1177\/0333102414547138","volume":"35","author":"Z Hepp","year":"2015","unstructured":"Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB (2015) Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia 35:478\u2013488. https:\/\/doi.org\/10.1177\/0333102414547138","journal-title":"Cephalalgia"},{"key":"5105_CR24","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s10194-020-01127-0","volume":"21","author":"G Lambru","year":"2020","unstructured":"Lambru G, Hill B, Murphy M, Tylova I, Andreou AP (2020) A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain 21:61. https:\/\/doi.org\/10.1186\/s10194-020-01127-0","journal-title":"J Headache Pain"},{"key":"5105_CR25","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1111\/7head.13946","volume":"60","author":"CR Houts","year":"2020","unstructured":"Houts CR, Wirth RJ, McGinley JS, Cady R, Lipton RB (2020) Determining thresholds for meaningful change for the headache impact test (HIT-6) total and item-specific scores in chronic migraine. Headache 60:2003\u20132013. https:\/\/doi.org\/10.1111\/7head.13946","journal-title":"Headache"},{"key":"5105_CR26","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1177\/0333102410379890","volume":"31","author":"M Yang","year":"2011","unstructured":"Yang M, Rendas-Baum R, Varon SF, Kosinski M (2011) Validation of the headache impact test (HIT-6TM) across episodic and chronic migraine. Cephalalgia 31:357\u2013367. https:\/\/doi.org\/10.1177\/0333102410379890","journal-title":"Cephalalgia"},{"key":"5105_CR27","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1177\/0333102411398400","volume":"31","author":"M Lanteri-Minet","year":"2011","unstructured":"Lanteri-Minet M, Duru G, Mudge M, Cottrell S (2011) Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review. Cephalalgia 31:837\u2013850. https:\/\/doi.org\/10.1177\/0333102411398400","journal-title":"Cephalalgia"},{"key":"5105_CR28","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s10194-009-0134-2","volume":"10","author":"M Pompili","year":"2009","unstructured":"Pompili M, Di Cosimo D, Innamorati M, Lester D, Tatarelli R, Martelletti P (2009) Psychiatric comorbidity in patients with chronic daily headache and migraine: a selective overview including personality traits and suicide risk. J Headache Pain 10:283\u2013290. https:\/\/doi.org\/10.1007\/s10194-009-0134-2","journal-title":"J Headache Pain"},{"key":"5105_CR29","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s10194-012-0480-3","volume":"13","author":"AL Teixeira","year":"2012","unstructured":"Teixeira AL, Coelho Costa EA, Albero da Silva A, Moreira dos Santos IA, Gomez RS, Kummer A, Lautherbach EC (2012) Psychiatric comorbidities of chronic migraine in community and tertiary care clinic samples. J Headache Pain 13:551\u2013555. https:\/\/doi.org\/10.1007\/s10194-012-0480-3","journal-title":"J Headache Pain"},{"key":"5105_CR30","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1177\/0333102420944842","volume":"40","author":"AH Seddik","year":"2020","unstructured":"Seddik AH, Branner JC, Ostwald DA, Schramm SH, Bierbaum M, Katsarava Z (2020) The socioeconomic burden of migraine: an evaluation of productivity losses due to migraine headache based on a population study in Germany. Cephalalgia 40:1551\u20131560. https:\/\/doi.org\/10.1177\/0333102420944842","journal-title":"Cephalalgia"},{"key":"5105_CR31","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/j1526-4610.2008.01142.x","volume":"48","author":"BL Peterlin","year":"2008","unstructured":"Peterlin BL, Calhoun AH, Siegel S, Mathew NT (2008) Rational combination therapy in refractory migraine. Headache 48:805\u2013819. https:\/\/doi.org\/10.1111\/j1526-4610.2008.01142.x","journal-title":"Headache"},{"key":"5105_CR32","doi-asserted-by":"publisher","first-page":"22","DOI":"10.18553\/jmcp.2014.20.1.22","volume":"20","author":"Z Hepp","year":"2014","unstructured":"Hepp Z, Bloudek LM, Varon SF (2014) Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm 20:22\u201333. https:\/\/doi.org\/10.18553\/jmcp.2014.20.1.22","journal-title":"J Manag Care Pharm"},{"key":"5105_CR33","doi-asserted-by":"publisher","unstructured":"Carlsen LN, Munksgaard SB, Jensen RH, Bendtsen L (2017) Complete detoxification is the most effective treatment of medication overuse-headache: a randomized controlled open-label trial. 38:225\u2013236. https:\/\/doi.org\/10.1177\/0333102417737779","DOI":"10.1177\/0333102417737779"},{"key":"5105_CR34","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1111\/j.1468-2982.2008.01659.x","volume":"28","author":"P Rossi","year":"2009","unstructured":"Rossi P, Faraoni JV, Nappi G (2009) Medication overuse headache: predictors and rate of relapse in migraine patients with low medical needs. A 1-year prospective study. Cephalalgia 28:1196\u20131200. https:\/\/doi.org\/10.1111\/j.1468-2982.2008.01659.x","journal-title":"Cephalalgia"},{"key":"5105_CR35","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s10194-019-1054-4","volume":"20","author":"R Ornello","year":"2019","unstructured":"Ornello R, Tiseo C, Frattale I, Perrotta G, Marini C, Pistoia F, Sacco S (2019) The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal. J Headache Pain 20:99. https:\/\/doi.org\/10.1186\/s10194-019-1054-4","journal-title":"J Headache Pain"},{"key":"5105_CR36","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1111\/head.13653","volume":"59","author":"JF Rothrock","year":"2019","unstructured":"Rothrock JF, Manack Adams A, Lipton RB, Silberstein RB, Jo E, Zhao X, Blumenfeld AM, FORWARD Study investigative group (2019) FORWARD study: evaluating the comparative effectiveness of onabotulinumtoxinA and topiramate for headache prevention in adults with chronic migraine. Headache 59:1700\u20131713. https:\/\/doi.org\/10.1111\/head.13653","journal-title":"Headache"},{"key":"5105_CR37","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s10194-020-01102-9","volume":"21","author":"R Ornello","year":"2020","unstructured":"Ornello R, Casalena A, Frattale I, Gabriele A, Affaitati G, Giamberardino MA, Assetta M, Maddestra M, Marzoli F, Viola S, Cerone D, Marini C, Pistoia F, Sacco S (2020) Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain 21:32. https:\/\/doi.org\/10.1186\/s10194-020-01102-9","journal-title":"J Headache Pain"},{"key":"5105_CR38","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1111\/head.13795","volume":"60","author":"K Falkenberg","year":"2020","unstructured":"Falkenberg K, Ronde Bjerg H, Olesen J (2020) Two-hour CGRP infusion causes gastrointestinal hyperactivity: possible relevance for CGRP antibody treatment. Headache 60:929\u2013937. https:\/\/doi.org\/10.1111\/head.13795","journal-title":"Headache"},{"key":"5105_CR39","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1177\/0333102419894559","volume":"40","author":"JL Brandes","year":"2020","unstructured":"Brandes JL, Diener HC, Dolezil D, Freeman MC, McAllister PJ, Winner P, Klatt J, Cheng S, Zhang F, Wen S, Ritter S, Lenz RA, Mikol DD (2020) The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving \u226550%, \u226575%, and 100% response. Cephalalgia 40:28\u201338. https:\/\/doi.org\/10.1177\/0333102419894559","journal-title":"Cephalalgia"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-021-05105-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-021-05105-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-021-05105-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T03:38:31Z","timestamp":1631763511000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-021-05105-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,5]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["5105"],"URL":"https:\/\/doi.org\/10.1007\/s10072-021-05105-5","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,5]]},"assertion":[{"value":"30 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Area Vasta Emilia Nord Ethics Committee (protocol number: 50\/2020\/OSS\/AOUMO). All procedures were conducted in accordance with the latest version of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Every subject signed an informed consent to participate the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Every subject signed an informed consent for the publication of the results of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MMC, FLC, and AF do not have conflicts of interest to declare. CB received travel grants from Allergan and Ely Lilly. SG received travel grants and honoraria from Allergan and Eli Lilly. LP is the Chief Scientific Officer of EDRA-LSWR Publishing Company and of Inpeco SA Total Lab Automation Company. In the last year, he has been a scientific consultant to AbbVie, USA; BCG, Switzerland; Boehringer-Ingelheim, Germany; Compass Pathways, UK; Johnson & Johnson, USA; Takeda, USA; VeraSci, USA; Vifor, Switzerland.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}